CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
rituximab [MabThera/Rituxan]drug
Likely dose
rituximab [MabThera/Rituxan] 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01998893
NCT01998893Phase 2Completed
CompareCT.gov

Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)

Hoffmann-La Roche·interventional·Posted Dec 2, 2013·Updated Dec 3, 2014

In Brief

A Phase 2 clinical trial evaluating rituximab [MabThera/Rituxan] for Non-Hodgkin's Lymphoma. Completed, enrolled 38 participants across 11 sites.

Detailed Summary

This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma. Patients will receive once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a second time in case of relapse (defined as progression after complete or partial response). The anticipated time on study treatment is \<3 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2, 2013
Enrollment StartJan 1, 1997
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11.1 yearsPosted 12.6 years ago

Interventions

rituximab [MabThera/Rituxan]drug

375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse